Retinal Disorders Treatment Market

Retinal Disorders Treatment Market (Indication: Macular Degeneration, Diabetic Retinopathy, Diabetic Macular Edema, and Others; Therapeutic Class: Anti-VEGF Agents and Others; Dosage Form: Gels, Eye Solutions, Capsules & Tablets, Eye Drops, and Ointments; Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Sales) – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020-2030

Advancements in Gene-therapy and Stem-cell Therapy to Bolster Market Growth

Retinal disorders have received considerable attention from researchers and other experts over the course of the past couple of decades. However, prior to that timeframe, retinal disorders were largely sidelined as the primary cause of blindness in the blindness programs in most of developing regions. A number of factors, including high costs involved in the treatment of retinal disorders, steep costs, and unreliability of the equipment utilized were some of the common factors that led to a sluggish growth of the retinal disorders treatment market in several developing regions. Over the past few years, advancements in technology coupled with promising findings from research and development activities have contributed to the overall development of the global retinal disorders treatment market– a trend that is projected to continue over the duration of the forecast period.

Increasing prevalence of retinal disorders in both, developing as well as developed regions of the world is expected to drive innovations, accelerate new treatments, and play an important role in increasing investments toward the overall development of the retinal disorders treatment market. Furthermore, the growing prevalence of diabetes around the world is another factor that is expected to augment the number of patients suffering from retinal disorders– a factor that is projected to boost the growth of the global retinal disorders treatment market during the assessment period. The increasing support offered by governments, particularly in developing regions has led to a considerable growth of the overall awareness pertaining to various retinal disorders due to which, the demand for retinal disorders treatment has witnessed a notable spike. This factor is anticipated to boost the prospects of the global retinal disorders treatment market during the stipulated timeframe of the study.

At the back of these factors, the global retinal disorders treatment market is on the course to surpass the US$ 19 Bn mark by the end of 2030.

Request a sample to get extensive insights into the Retinal Disorders Treatment Market

New Technologies Set to Transform Future of Retinal Disorders Treatment

Technological advancements are set to play a key role in the overall growth of the global retinal disorders treatment market in the upcoming years. Groundbreaking breakthroughs and advancements in bionics, genetics, and stem-cell therapy are expected to transform the future of retinal disorders treatment in the upcoming decade. In developed regions wherein the preventable causes of blindness are detected early, owing to routine checkups and robust healthcare ecosystem, retinal degeneration has emerged as one of the top causes of blindness or visual impairment. Advancements across several new frontiers are expected to pave the way for new retinal disorders treatments for all the major forms of retinal disorders. Advancements in gene therapy, functional prostheses, and growing interest in bionic eyes are projected to play a vital role in boosting the growth of the global retinal disorders treatment market during the forecast period. While gene therapy is likely to emerge as a promising retinal disorder treatment, cell regeneration or stem-cell therapy has offered considerable promise in the treatment of blindness, especially in the later stages of the disease. Advancements in technology coupled with research and development activities are expected to play a key role in boosting the growth of the global retinal disorders treatment market during the assessment period.

To understand how our report can bring difference to your business strategy, Ask for a brochure

Links Between COVID-19 and Microvascular Alterations to Increase Demand

The onset of the COVID-19 pandemic is expected to have a moderate impact on the overall growth of the global retinal disorders treatment market in 2020. While the major focus is projected to remain toward the discovery of new vaccine, research and development activities in other branches of the medical sectors are likely to continue as per the initial timeline. Research activities are also anticipated to evaluate the presence of retinal alterations among patients suffering from the novel COVID-19 infection. Due to the constant fear of contracting the virus, doctors and specialists are expected to rely on telehealth services. Although the trends suggest that patients are willing to delay retinal disorders treatment due to the ongoing pandemic, the market is likely to show signs of recovery toward the last quarter of 2020.

Stuck in a neck-to-neck competition with other brands? Request a custom report on Retinal Disorders Treatment Market

Analysts’ Viewpoint

The global retinal disorders treatment market is anticipated to expand at a healthy CAGR of ~7% during the forecast period. The market growth is primarily driven by increasing prevalence of retinal disorders worldwide, advancements in technology, including gene therapy and stem-cell therapy, research and development activities, and rising awareness regarding recent research findings and progress made in the retinal disorders treatment market. Market players should focus on research and development activities and continue to explore the potential of different technologies that could be utilized for retinal disorders treatment.

Retinal Disorders Treatment Market: Overview

  • Macular degeneration is of two types: wet age-related macular degeneration and dry age-related macular degeneration. Diabetic retinopathy is one of the common diabetic eye disorders characterized by damaged blood vessels in the retina. The damaged blood vessels and nerves lead to vision impairment, blurring of vision, and eye hemorrhage. If left untreated, it could lead to retinal detachment and blindness.
  • The global retinal disorders treatment market is projected to expand at a moderate pace due to rise in prevalence of retinal disorders, owing to increase in geriatric patient population, new product launches, high annual cost of therapy (ACOT), and surge in number of eye care centers leading to increased product utilization

Retinal Disorders Treatment Market: Drivers

  • Rise in prevalence of retinal disorders due to increase in geriatric patient population boosts the growth of the global retinal disorders treatment market. Age-related macular degeneration (AMD) is the leading cause of irreversible blindness across the globe, affecting around 196 million in 2019 and anticipated to increase to 288 million by 2040. Prevalence estimates are on late AMD, involving neovascular AMD, and geographic atrophy. In the U.S., the number of patients suffering from AMD is 11 million. This number is expected to double to nearly 22 million by 2050.
  • Prevalence of other retinal disorders was 93 million people with diabetic retinopathy, 21 million people with diabetic macular edema, and 28 million people with vision-threatening diabetic retinopathy
  • New product launches and high annual cost of therapy (ACOT) also fuel the growth of the retinal disorders treatment market in terms of revenue. New anti-vascular endothelial growth factor (anti-VEGF) drugs have been launched to treat the neovascular (wet) form of AMD, along with numerous other retinal conditions. Anti-VEGFs have improved therapy outcomes for these conditions; however, these incur high cost.
  • In 2007, Lucentis became the first anti-VEGF launched in Canada and approved for wet AMD as well as other major retinal diseases. It was quickly recognized as the new gold standard for treatment. In 2013, Eylea was also approved for AMD and launched at a marginally lower price; other indications were added later.

Increase in Healthcare Spending and Improvement in Healthcare Infrastructure

  • Increase in R&D activities, rise in number of patients suffering from diseases, and rapid expansion of healthcare and biopharmaceutical industries in developed and developing countries are likely to boost advancements in therapies in the retinal disorders treatment market during the forecast period
  • For instance, Lucentis and Eylea accounted for 2.8% of total pharmaceutical sales in Canada in 2017

Market Segmentation: Retinal Disorders Treatment Market

  • In terms of indication, the global retinal disorders treatment market has been divided into macular degeneration, diabetic retinopathy, diabetic macular edema, and others. Macular degeneration has been split into dry macular degeneration and wet macular degeneration.
  • Based on therapeutic class, the global retinal disorders treatment market has been categorized into anti-VEGF agents and others
  • In terms of dosage form, the global retinal disorders treatment market has been segregated into gels, eye solutions, capsules & tablets, eye drops, and ointments
  • Based on distribution channel, the global retinal disorders treatment market has been classified into hospital pharmacies, retail pharmacies, and online sales
  • Each of the segments has been analyzed in detail for retinal disorders treatment trends, recent trends & developments, drivers, restraints, opportunities, and useful insights. The retinal disorders treatment market report provides current and future revenue (US$ Mn) for each of these segments for the period from 2018 to 2030, considering 2019 as the base year. The compound annual growth rate (% CAGR) has been provided for each segment and market from 2020 to 2030, along with market size estimations.

Regional Overview: Retinal Disorders Treatment Market

  • In terms of region, the global retinal disorders treatment market has been segmented into the U.S., Europe, China, Russia, and Rest of the world
  • The U.S. dominated the global retinal disorder treatment market in 2019 due to highly structured healthcare industry, early adoption of new products, and presence of major players. The retinal disorders treatment market in China is projected to expand at the highest CAGR during the forecast period, owing to a large untapped population and rise in the adoption of treatment. Diagnosis and treatment rates have increased due to rise in disposable income and health awareness. This has led to an increase in the adoption of macular degeneration drugs.
  • Current and future market sizes in terms of value (US$ Mn) of these regional markets and major countries have been provided in the report for the period from 2018 to 2030, along with their CAGRs for the period from 2020 to 2030
  • The study also offers a list of recommendations, highlights, and useful insights of the market, which are estimated to help new companies willing to enter the retinal disorders treatment market and existing companies to increase market share, and in the decision-making process

Major Players

  • The report concludes with the company profiles section that includes key information about the major players in the global retinal disorders treatment market
  • Leading players analyzed in the report are
    • Allergan plc
    • Bayer AG, F.
    • Hoffmann-La Roche Ltd.
    • Graybug Vision, Inc.
    • Kubota Pharmaceutical Holdings Co., Ltd.
    • Novartis AG, Pfizer, Inc.
    • Regeneron Pharmaceuticals, Inc.
    • Santen Pharmaceutical Co., Ltd.
    • Takeda Pharmaceutical Company Limited
  • Each of these players has been profiled in the report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments

Retinal Disorders Treatment Market – Segmentation

TMR’s study on the global retinal disorders treatment market includes information divided into five segments: indication, dosage form, therapeutic class, distribution channel, and region. Changing industry trends and other crucial market dynamics associated with these segments of the global retinal disorders treatment market have been discussed in detail.

Indication

  • Macular Degeneration
  • Diabetic Retinopathy
  • Diabetic Macular Edema
  • Others

Therapeutic Class

  • Anti-VEGF Agents
  • Others

Dosage Form

  • Gels
  • Eye Solutions
  • Capsules & Tablets
  • Eye Drops
  • Ointments

Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Sales

Region

  • U.S.
  • Europe
  • China
  • Russia
  • Rest of the World (RoW)

Frequently Asked Questions

What is the total market worth of retinal disorders treatment market?

The global retinal disorders treatment market was worth US$ 9.18 Bn and is projected to reach a value of US$ 19 Bn by the end of 2030

What is the anticipated CAGR of retinal disorders treatment market in forecast period?

Retinal disorders treatment market is anticipated to grow at a CAGR of 7% during the forecast period

Which region is expected to project highest market share in retinal disorders treatment market?

North America accounted for a major share of the global retinal disorders treatment market

What are the key driving factors for growth of retinal disorders treatment market?

Retinal disorders treatment market is driven by increasing prevalence of retinal disorders worldwide, advancements in technology, including gene therapy and stem-cell therapy, research and development activities, and rising awareness regarding recent research findings

Who are the key players in the global retinal disorders treatment market?

Key players in the global retinal disorders treatment market include Allergan plc, Bayer AG, F. Hoffmann-La Roche Ltd., Graybug Vision, Inc., Kubota Pharmaceutical Holdings Co., Ltd., Novartis AG, Pfizer, Inc., Regeneron Pharmaceuticals, Inc., Santen Pharmaceutical Co., Ltd., and Takeda Pharmaceutical Company Limited

    1. Preface

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary: Global Retinal Disorders Treatment Market

    4. Market Overview

        4.1.  Introduction & Overview

        4.2. Market Dynamics

            4.2.1. Drivers

            4.2.2. Restraints

            4.2.3. Opportunities

        4.3. Global Retinal Disorders Treatment Market Analysis and Forecast, 2018–2030

    5. Market Outlook

        5.1. COVID-19 Pandemics Impact on Industry

        5.2. Clinical Trial Analysis

        5.3. Regulatory Scenario

        5.4. Pipeline Analysis

        5.5. Key Potential Customers

        5.6. Key Vendor and Distributor Analysis

        5.7. Key Industry Events

        5.8. Reimbursement Scenario

        5.9. Retinal Disorders: Epidemiology Forecast

    6. Global Retinal Disorders Treatment Market Analysis and Forecast, by Indication

        6.1. Introduction & Definition    

        6.2. Global Retinal Disorders Treatment Market Value (US$ Mn) Forecast, by Indication, 2018–2030

            6.2.1. Macular Degeneration

                6.2.1.1. Dry Macular Degeneration

                6.2.1.2. Wet Macular Degeneration

            6.2.2. Diabetic Retinopathy

            6.2.3. Diabetic Macular Edema

            6.2.4. Others

        6.3. Global Retinal Disorders Treatment Market Attractiveness Analysis, by Indication

    7. Global Retinal Disorders Treatment Market Analysis and Forecast, by Therapeutic Class

        7.1. Introduction & Definition    

        7.2. Global Retinal Disorders Treatment Market Value (US$ Mn) Forecast, by Therapeutic Class, 2018–2030

            7.2.1. Anti-VEGF Agents

            7.2.2. Others

        7.3. Global Retinal Disorders Treatment Market Attractiveness Analysis, by Therapeutic Class

    8. Global Retinal Disorders Treatment Market Analysis and Forecast, by Dosage Form

        8.1. Introduction & Definition    

        8.2. Global Retinal Disorders Treatment Market Value (US$ Mn) Forecast, by Dosage Form, 2018–2030

            8.2.1. Gels

            8.2.2. Eye Solutions

            8.2.3. Capsules & Tablets

            8.2.4. Eye Drops

            8.2.5. Ointments

        8.3. Global Retinal Disorders Treatment Market Attractiveness Analysis, by Dosage Form

    9. Global Retinal Disorders Treatment Market Analysis and Forecast, by Distribution Channel

        9.1. Introduction & Definition    

        9.2. Global Retinal Disorders Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

            9.2.1. Hospital Pharmacies

            9.2.2. Retail Pharmacies

            9.2.3. Online Sales

        9.3. Global Retinal Disorders Treatment Market Attractiveness Analysis, by Distribution Channel

    10. Global Retinal Disorders Treatment Market Analysis and Forecast, by Region

        10.1. Key Findings

        10.2. Global Retinal Disorders Treatment Market Value (US$ Mn) Forecast, by Region

            10.2.1. U.S.

            10.2.2. Europe

            10.2.3. China

            10.2.4. Russia

            10.2.5. Rest of the World (RoW)

        10.3. Global Retinal Disorders Treatment Market Attractiveness Analysis, by Region

    11. U.S. Retinal Disorders Treatment Market Analysis and Forecast

        11.1. Introduction

        11.2. U.S. Retinal Disorders Treatment Market Value (US$ Mn) Forecast, by Indication, 2018–2030

            11.2.1. Macular Degeneration

                11.2.1.1. Dry Macular Degeneration

                11.2.1.2. Wet Macular Degeneration

            11.2.2. Diabetic Retinopathy

            11.2.3. Diabetic Macular Edema

            11.2.4. Others

        11.3. U.S. Retinal Disorders Treatment Market Value (US$ Mn) Forecast, by Therapeutic Class, 2018–2030

            11.3.1. Anti-VEGF Agents

            11.3.2. Others

        11.4. U.S. Retinal Disorders Treatment Market Value (US$ Mn) Forecast, by Dosage Form, 2018–2030

            11.4.1. Gels

            11.4.2. Eye Solutions

            11.4.3. Capsules & Tablets

            11.4.4. Eye Drops

            11.4.5. Ointments

        11.5. U.S. Retinal Disorders Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

            11.5.1. Hospital Pharmacies

            11.5.2. Retail Pharmacies

            11.5.3. Online Sales

        11.6. U.S. Retinal Disorders Treatment Market Attractiveness Analysis

            11.6.1. By Indication

            11.6.2. By Therapeutic Class

            11.6.3. By Dosage Form

            11.6.4. By Distribution Channel

    12. Europe Retinal Disorders Treatment Market Analysis and Forecast

        12.1. Introduction

        12.2. Europe Retinal Disorders Treatment Market Value (US$ Mn) Forecast, by Indication, 2018–2030

            12.2.1. Macular Degeneration

                12.2.1.1. Dry Macular Degeneration

                12.2.1.2. Wet Macular Degeneration

            12.2.2. Diabetic Retinopathy

            12.2.3. Diabetic Macular Edema

            12.2.4. Others

        12.3. Europe Retinal Disorders Treatment Market Value (US$ Mn) Forecast, by Therapeutic Class, 2018–2030

            12.3.1. Anti-VEGF Agents

            12.3.2. Others

        12.4. Europe Retinal Disorders Treatment Market Value (US$ Mn) Forecast, by Dosage Form, 2018–2030

            12.4.1. Gels

            12.4.2. Eye Solutions

            12.4.3. Capsules & Tablets

            12.4.4. Eye Drops

            12.4.5. Ointments

        12.5. Europe Retinal Disorders Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

            12.5.1. Hospital Pharmacies

            12.5.2. Retail Pharmacies

            12.5.3. Online Sales

        12.6. Europe Retinal Disorders Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

            12.6.1. Germany

            12.6.2. U.K.

            12.6.3. France

            12.6.4. Spain

            12.6.5. Italy

            12.6.6. Rest of Europe

        12.7. Europe Retinal Disorders Treatment Market Attractiveness Analysis

            12.7.1. By Indication

            12.7.2. By Therapeutic Class

            12.7.3. By Dosage Form

            12.7.4. By Distribution Channel

            12.7.5. By Country/Sub-region

    13. China Retinal Disorders Treatment Market Analysis and Forecast

        13.1. Introduction

        13.2. China Retinal Disorders Treatment Market Value (US$ Mn) Forecast, by Indication, 2018–2030

            13.2.1. Macular Degeneration

                13.2.1.1. Dry Macular Degeneration

                13.2.1.2. Wet Macular Degeneration

            13.2.2. Diabetic Retinopathy

            13.2.3. Diabetic Macular Edema

            13.2.4. Others

        13.3. China Retinal Disorders Treatment Market Value (US$ Mn) Forecast, by Therapeutic Class, 2018–2030

            13.3.1. Anti-VEGF Agents

            13.3.2. Others

        13.4. China Retinal Disorders Treatment Market Value (US$ Mn) Forecast, by Dosage Form, 2018–2030

            13.4.1. Gels

            13.4.2. Eye Solutions

            13.4.3. Capsules & Tablets

            13.4.4. Eye Drops

            13.4.5. Ointments

        13.5. China Retinal Disorders Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

            13.5.1. Hospital Pharmacies

            13.5.2. Retail Pharmacies

            13.5.3. Online Sales

        13.6. China Retinal Disorders Treatment Market Attractiveness Analysis

            13.6.1. By Indication

            13.6.2. By Therapeutic Class

            13.6.3. By Dosage Form

            13.6.4. By Distribution Channel

    14. Russia Retinal Disorders Treatment Market Analysis and Forecast

        14.1. Introduction

        14.2. Russia Retinal Disorders Treatment Market Value (US$ Mn) Forecast, by Indication, 2018–2030

            14.2.1. Macular Degeneration

                14.2.1.1. Dry Macular Degeneration

                14.2.1.2. Wet Macular Degeneration

            14.2.2. Diabetic Retinopathy

            14.2.3. Diabetic Macular Edema

            14.2.4. Others

        14.3. Russia Retinal Disorders Treatment Market Value (US$ Mn) Forecast, by Therapeutic Class, 2018–2030

            14.3.1. Anti-VEGF Agents

            14.3.2. Others

        14.4. Russia Retinal Disorders Treatment Market Value (US$ Mn) Forecast, by Dosage Form, 2018–2030

            14.4.1. Gels

            14.4.2. Eye Solutions

            14.4.3. Capsules & Tablets

            14.4.4. Eye Drops

            14.4.5. Ointments

        14.5. Russia Retinal Disorders Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

            14.5.1. Hospital Pharmacies

            14.5.2. Retail Pharmacies

            14.5.3. Online Sales

        14.6. Russia Retinal Disorders Treatment Market Attractiveness Analysis

            14.6.1. By Indication

            14.6.2. By Therapeutic Class

            14.6.3. By Dosage Form

            14.6.4. By Distribution Channel

    15. Rest of the World Retinal Disorders Treatment Market Analysis and Forecast

        15.1. Introduction

        15.2. Rest of the World Retinal Disorders Treatment Market Value (US$ Mn) Forecast, by Indication, 2018–2030

            15.2.1. Macular Degeneration

                15.2.1.1. Dry Macular Degeneration

                15.2.1.2. Wet Macular Degeneration

            15.2.2. Diabetic Retinopathy

            15.2.3. Diabetic Macular Edema

            15.2.4. Others

        15.3. Rest of the World Retinal Disorders Treatment Market Value (US$ Mn) Forecast, by Therapeutic Class, 2018–2030

            15.3.1. Anti-VEGF Agents

            15.3.2. Others

        15.4. Rest of the World Retinal Disorders Treatment Market Value (US$ Mn) Forecast, by Dosage Form, 2018–2030

            15.4.1. Gels

            15.4.2. Eye Solutions

            15.4.3. Capsules & Tablets

            15.4.4. Eye Drops

            15.4.5. Ointments

        15.5. Rest of the World Retinal Disorders Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

            15.5.1. Hospital Pharmacies

            15.5.2. Retail Pharmacies

            15.5.3. Online Sales

        15.6. Rest of the World Retinal Disorders Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

            15.6.1. Canada

            15.6.2. India

            15.6.3. Japan

            15.6.4. Australia

            15.6.5. Brazil

            15.6.6. Rest of Rest of the World

        15.7. Rest of the World Retinal Disorders Treatment Market Attractiveness Analysis

            15.7.1. By Indication

            15.7.2. By Therapeutic Class

            15.7.3. By Dosage Form

            15.7.4. By Distribution Channel

            15.7.5. By Country/Sub-region

    16. Competition Landscape

        16.1. Market Position Analysis, by Company, 2019

        16.2. Company Profiles

            16.2.1. Allergan plc

                16.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.2.1.2. Growth Strategies

                16.2.1.3. SWOT Analysis

            16.2.2. Bayer AG

                16.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.2.2.2. Growth Strategies

                16.2.2.3. SWOT Analysis

            16.2.3. F. Hoffmann-La Roche Ltd.

                16.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.2.3.2. Growth Strategies

                16.2.3.3. SWOT Analysis

            16.2.4. Graybug Vision, Inc.

                16.2.4.1. Company Overview (HQ, Business Segments)

                16.2.4.2. Growth Strategies

                16.2.4.3. SWOT Analysis

            16.2.5. Kubota Pharmaceutical Holdings Co., Ltd.

                16.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.2.5.2. Growth Strategies

                16.2.5.3. SWOT Analysis

            16.2.6. Novartis AG

                16.2.6.1. Company Overview (HQ, Business Segments)

                16.2.6.2. Growth Strategies

                16.2.6.3. SWOT Analysis

            16.2.7. Pfizer, Inc.

                16.2.7.1. Company Overview (HQ, Business Segments)

                16.2.7.2. Growth Strategies

                16.2.7.3. SWOT Analysis

            16.2.8. Regeneron Pharmaceuticals, Inc.

                16.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.2.8.2. Growth Strategies

                16.2.8.3. SWOT Analysis

            16.2.9. Santen Pharmaceutical Co., Ltd.

                16.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.2.9.2. Growth Strategies

                16.2.9.3. SWOT Analysis

            16.2.10. Takeda Pharmaceutical Company Limited

                16.2.10.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.2.10.2. Growth Strategies

                16.2.10.3. SWOT Analysis

    List of Tables

    Table 01: Global Retinal Disorders Treatment Market Value (US$ Mn) Forecast, by Indication, 2018–2030

    Table 02: Global Retinal Disorders Treatment Market Value (US$ Mn) Forecast, by Therapeutic Class, 2018–2030

    Table 03: Global Retinal Disorders Treatment Market Value (US$ Mn) Forecast, by Dosage Form, 2018–2030

    Table 04: Global Retinal Disorders Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

    Table 05: Global Retinal Disorders Treatment Market Value (US$ Mn) Forecast, by Region, 2018–2030

    Table 06: U.S. Retinal Disorders Treatment Market Value (US$ Mn) Forecast, by Indication, 2018–2030

    Table 07: U.S. Retinal Disorders Treatment Market Value (US$ Mn) Forecast, by Therapeutic Class, 2018–2030

    Table 08: U.S. Retinal Disorders Treatment Market Value (US$ Mn) Forecast, by Dosage Form, 2018–2030

    Table 09: U.S. Retinal Disorders Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

    Table 10: Europe Retinal Disorders Treatment Market Value (US$ Mn) Forecast, by Indication, 2018–2030

    Table 11: Europe Retinal Disorders Treatment Market Value (US$ Mn) Forecast, by Therapeutic Class, 2018–2030

    Table 12: Europe Retinal Disorders Treatment Market Value (US$ Mn) Forecast, by Dosage Form, 2018–2030

    Table 13: Europe Retinal Disorders Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

    Table 14: Europe Retinal Disorders Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

    Table 15: China Retinal Disorders Treatment Market Value (US$ Mn) Forecast, by Indication, 2018–2030

    Table 16: China Retinal Disorders Treatment Market Value (US$ Mn) Forecast, by Therapeutic Class, 2018–2030

    Table 17: China Retinal Disorders Treatment Market Value (US$ Mn) Forecast, by Dosage Form, 2018–2030

    Table 18: China Retinal Disorders Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

    Table 19: Russia Retinal Disorders Treatment Market Value (US$ Mn) Forecast, by Indication, 2018–2030

    Table 20: Russia Retinal Disorders Treatment Market Value (US$ Mn) Forecast, by Therapeutic Class, 2018–2030

    Table 21: Russia Retinal Disorders Treatment Market Value (US$ Mn) Forecast, by Dosage Form, 2018–2030

    Table 22: Russia Retinal Disorders Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

    Table 23: Rest of the World (ROW) Retinal Disorders Treatment Market Value (US$ Mn) Forecast, by Indication, 2018–2030

    Table 24: Rest of the World (ROW) Retinal Disorders Treatment Market Value (US$ Mn) Forecast, by Therapeutic Class, 2018–2030

    Table 25: Rest of the World (ROW) Retinal Disorders Treatment Market Value (US$ Mn) Forecast, by Dosage Form, 2018–2030

    Table 26: Rest of the World (ROW) Retinal Disorders Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

    Table 27: Rest of the World (ROW) Retinal Disorders Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

    List of Figures

    Figure 01: Global Retinal Disorders Treatment Market Value (US$ Mn) Forecast, 2018–2030

    Figure 02: Global Retinal Disorders Treatment Market Value Share, by Indication, 2019

    Figure 03: Global Retinal Disorders Treatment Market Value Share, by Dosage Form, 2019

    Figure 04: Global Retinal Disorders Treatment Market Value Share, by Therapeutic Class, 2019

    Figure 05: Global Retinal Disorders Treatment Market Value Share, by Distribution Channel, 2019

    Figure 06: Global Retinal Disorders Treatment Market Value Share, by Region, 2019

    Figure 07: Clinical Trial Analysis, by Phase

    Figure 08: Clinical Trial Analysis, by Status

    Figure 09: Clinical Trial Analysis, by Completion and Termination Rate

    Figure 10: Clinical Trial Analysis, by Region

    Figure 11: Global Retinal Disorders Treatment Market Value Share Analysis, by Indication, 2019 and 2030

    Figure 12: Global Retinal Disorders Treatment Market Attractiveness Analysis, by Indication, 2020–2030

    Figure 13: Global Retinal Disorders Treatment Market Value (US$ Mn), by Macular Degeneration, 2018–2030

    Figure 14: Global Retinal Disorders Treatment Market Value (US$ Mn), by Diabetic Retinopathy, 2018–2030

    Figure 15: Global Retinal Disorders Treatment Market Value (US$ Mn), by Diabetic Macular Edema, 2018–2030

    Figure 16: Global Retinal Disorders Treatment Market Value (US$ Mn), by Others (retinal vein occlusion, etc.), 2018–2030

    Figure 17: Global Retinal Disorders Treatment Market Value Share Analysis, by Therapeutic Class, 2019 and 2030

    Figure 18: Global Retinal Disorders Treatment Market Attractiveness Analysis, by Therapeutic Class, 2020–2030

    Figure 19: Global Retinal Disorders Treatment Market Value (US$ Mn), by Anti-VEGF Agents, 2018–2030

    Figure 20: Global Retinal Disorders Treatment Market Value (US$ Mn), by Others (anti-inflammatory drugs, etc.), 2018–2030

    Figure 21: Global Retinal Disorders Treatment Market Value Share Analysis, by Dosage Form, 2019 and 2030

    Figure 22: Global Retinal Disorders Treatment Market Attractiveness Analysis, by Dosage Form, 2020–2030

    Figure 23: Global Retinal Disorders Treatment Market Value (US$ Mn), by Gels, 2018–2030

    Figure 24: Global Retinal Disorders Treatment Market Value (US$ Mn), by Eye Solutions, 2018–2030

    Figure 25: Global Retinal Disorders Treatment Market Value (US$ Mn), by Capsules & Tablets, 2018–2030

    Figure 26: Global Retinal Disorders Treatment Market Value (US$ Mn), by Eye Drops, 2018–2030

    Figure 27: Global Retinal Disorders Treatment Market Value (US$ Mn), by Ointments, 2018–2030

    Figure 28: Global Retinal Disorders Treatment Market Value Share Analysis, by Distribution Channel, 2019 and 2030

    Figure 29: Global Retinal Disorders Treatment Market Attractiveness Analysis, by Distribution Channel, 2020–2030

    Figure 30: Global Retinal Disorders Treatment Market Value (US$ Mn), by Hospital Pharmacies, 2018–2030

    Figure 31: Global Retinal Disorders Treatment Market Value (US$ Mn), by Retail Pharmacies, 2018–2030

    Figure 32: Global Retinal Disorders Treatment Market Value (US$ Mn), by Online Sales, 2018–2030

    Figure 33: Global Retinal Disorders Treatment Market Value Share Analysis, by Region, 2019 and 2030

    Figure 34: Global Retinal Disorders Treatment Market Analysis, by Region

    Figure 35: U.S. Retinal Disorders Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030

    Figure 36: U.S. Retinal Disorders Treatment Market Value Share Analysis, by Indication, 2019 and 2030

    Figure 37: U.S. Retinal Disorders Treatment Market Attractiveness Analysis, by Indication, 2020–2030

    Figure 38: U.S. Retinal Disorders Treatment Market Value Share Analysis, by Therapeutic Class, 2019 and 2030

    Figure 39: U.S. Retinal Disorders Treatment Market Attractiveness Analysis, by Therapeutic Class, 2020–2030

    Figure 40: U.S. Retinal Disorders Treatment Market Value Share Analysis, by Dosage Form, 2019 and 2030

    Figure 41: U.S. Retinal Disorders Treatment Market Attractiveness Analysis, by Dosage Form, 2020–2030

    Figure 42: U.S. Retinal Disorders Treatment Market Value Share Analysis, by Distribution Channel, 2019 and 2030

    Figure 43: U.S. Retinal Disorders Treatment Market Attractiveness Analysis, by Distribution Channel, 2020–2030

    Figure 44: Europe Retinal Disorders Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030

    Figure 45: Europe Retinal Disorders Treatment Market Value Share Analysis, by Indication, 2019 and 2030

    Figure 46: Europe Retinal Disorders Treatment Market Attractiveness Analysis, by Indication, 2020–2030

    Figure 47: Europe Retinal Disorders Treatment Market Attractiveness Analysis, by Therapeutic Class, 2020–2030

    Figure 48: Europe Retinal Disorders Treatment Market Value Share Analysis, by Dosage Form, 2019 and 2030

    Figure 49: Europe Retinal Disorders Treatment Market Attractiveness Analysis, by Dosage Form, 2020–2030

    Figure 50: Europe Retinal Disorders Treatment Market Value Share Analysis, by Distribution Channel, 2019 and 2030

    Figure 51: Europe Retinal Disorders Treatment Market Attractiveness Analysis, by Distribution Channel, 2020–2030

    Figure 52: Europe Retinal Disorders Treatment Market Value Share Analysis, by Country/Sub-region, 2019 and 2030

    Figure 53: Europe Retinal Disorders Treatment Market Attractiveness Analysis, by Country/Sub-region, 2020–2030

    Figure 54: China Retinal Disorders Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030

    Figure 55: China Retinal Disorders Treatment Market Value Share Analysis, by Indication, 2019 and 2030

    Figure 56: China Retinal Disorders Treatment Market Attractiveness Analysis, by Indication, 2020–2030

    Figure 57: China Retinal Disorders Treatment Market Value Share Analysis, by Therapeutic Class, 2019 and 2030

    Figure 58: China Retinal Disorders Treatment Market Attractiveness Analysis, by Therapeutic Class, 2020–2030

    Figure 59: China Retinal Disorders Treatment Market Value Share Analysis, by Dosage Form, 2019 and 2030

    Figure 60: China Retinal Disorders Treatment Market Attractiveness Analysis, by Dosage Form, 2020–2030

    Figure 61: China Retinal Disorders Treatment Market Value Share Analysis, by Distribution Channel, 2019 and 2030

    Figure 62: China Retinal Disorders Treatment Market Attractiveness Analysis, by Distribution Channel, 2020–2030

    Figure 63: Russia Retinal Disorders Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030

    Figure 64: Russia Retinal Disorders Treatment Market Value Share Analysis, by Indication, 2019 and 2030

    Figure 65: Russia Retinal Disorders Treatment Market Attractiveness Analysis, by Indication, 2020–2030

    Figure 66: Russia Retinal Disorders Treatment Market Value Share Analysis, by Therapeutic Class, 2019 and 2030

    Figure 67: Russia Retinal Disorders Treatment Market Attractiveness Analysis, by Therapeutic Class, 2020–2030

    Figure 68: Russia Retinal Disorders Treatment Market Value Share Analysis, by Dosage Form, 2019 and 2030

    Figure 69: Russia Retinal Disorders Treatment Market Attractiveness Analysis, by Dosage Form, 2020–2030

    Figure 70: Russia Retinal Disorders Treatment Market Value Share Analysis, by Distribution Channel, 2019 and 2030

    Figure 71: Russia Retinal Disorders Treatment Market Attractiveness Analysis, by Distribution Channel, 2020–2030

    Figure 72: Rest of the World (ROW) Retinal Disorders Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030

    Figure 73: Rest of the World (ROW) Retinal Disorders Treatment Market Value Share Analysis, by Indication, 2019 and 2030

    Figure 74: Rest of the World (ROW) Retinal Disorders Treatment Market Attractiveness Analysis, by Indication, 2020–2030

    Figure 75: Rest of the World (ROW) Retinal Disorders Treatment Market Value Share Analysis, by Therapeutic Class, 2019 and 2030

    Figure 76: Rest of the World (ROW) Retinal Disorders Treatment Market Attractiveness Analysis, by Therapeutic Class, 2020–2030

    Figure 77: Rest of the World (ROW) Retinal Disorders Treatment Market Value Share Analysis, by Dosage Form, 2019 and 2030

    Figure 78: Rest of the World (ROW) Retinal Disorders Treatment Market Attractiveness Analysis, by Dosage Form, 2020–2030

    Figure 79: Rest of the World (ROW) Retinal Disorders Treatment Market Value Share Analysis, by Distribution Channel, 2019 and 2030

    Figure 80: Rest of the World (ROW) Retinal Disorders Treatment Market Attractiveness Analysis, by Distribution Channel, 2020–2030

    Figure 81: Rest of the World (ROW) Retinal Disorders Treatment Market Value Share Analysis, by Country/Sub-region, 2019 and 2030

    Figure 82: Rest of the World (ROW) Retinal Disorders Treatment Market Attractiveness Analysis, by Country/Sub-region, 2020–2030

Copyright © Transparency Market Research, Inc. All Rights reserved